Minocycline inhibits neuronal death and glial activation induced by β‐amyloid peptide in rat hippocampus
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Minocycline, a second‐generation tetracycline compound, has been examined as a neuroprotectant in β‐amyloid (Aβ)‐injected rat hippocampus. At 7 days post‐injection, Aβ 1‐42 caused a significant loss of granule cell layer neurons (28% reduction) compared to control uninjected hippocampus. Hippocampal injection of Aβ peptide also led to marked gliosis with numbers of microglia (increased by 26‐fold) and immunoreactivity of astrocytes (increased by 11‐fold) relative to control, as determined from immunohistochemical analysis. Intraperitoneal administration of minocycline significantly reduced neuronal loss induced by Aβ 1‐42 (by 80%) and also diminished numbers of microglia (by 69%) and astrocytes (by 36%) relative to peptide alone. Peptide injection increased expression of cyclooxygenase‐2 (COX‐2) in most (about 70%) of granule cells, a subset (about 20%) of microglia, but not in astrocytes; in the presence of minocycline, COX‐2 immunostaining was abolished in microglia. The results from this study suggest that minocycline may have efficacy in the treatment of AD. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 3×
“, 2000), Parkinson’s disease (PD) (Wu et al., 2002), multiple sclerosis (Popovic”
BackgroundResultRisk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“The progression of AD is characterized by activation of microglia (Cagnin et al., 2001), leading to enhancement in expression of inducible cyclooxygenase-2 (COX-2) and increased production of inflammatory mediators, such as nitric oxide, tumor necrosis factor- (TNF- ), interleukin-1 (IL-1 ), and…”
BackgroundCombs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721 · cited 1×
“Also, activated microglia have been shown to produce factors such as pro-inflammatory cytokines and ROS, which can be toxic to neurons (Combs et al., 2001; Lue et al., 2001).”
BackgroundCoraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., & El Khoury, J. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64354-4 · Cited by 398 · cited 1×
“…enhancement in expression of inducible cyclooxygenase-2 (COX-2) and increased production of inflammatory mediators, such as nitric oxide, tumor necrosis factor- (TNF- ), interleukin-1 (IL-1 ), and reactive oxygen species (ROS) (Benveniste et al., 2001; McGeer and McGeer, 2001; Coraci et al., 2002).”
BackgroundWeldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O’Hare, E., Esler, W. P., Maggio, J. E., & Mantyh, P. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02161.1998 · Cited by 348
Inhibition of autoimmune encephalomyelitis by a tetracycline
Popovic, N., Schubart, A., Goetz, B. D., Zhang, S., Linington, C., & Duncan, I. D. (2002) · Annals of Neurology · doi:10.1002/ana.10092 · Cited by 295 · cited 1×
“Our present data, combined with previous work, show clinical efficacy of minocycline in a wide spectrum of neurodegenerative diseases (Yrjanheikki et al., 1999; Chen et al., 2000; Popovic et al., 2002; Wu et al., 2002).”
Result
Cited by
Microglia Biology in Health and Disease
Garden, G. A., & Möller, T. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9015-5 · Cited by 496
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Ryu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406
Self-citationTargeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Vincent, J. A., & Mohr, S. (2007) · Diabetes · doi:10.2337/db06-0427 · Cited by 298
McLarnon, J. G., Ryu, J. K., Walker, D. G., & Choi, H. B. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240470.97295.d3 · Cited by 281
Self-citationMinocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279
Hua, X., Svensson, C. I., Matsui, T., Fitzsimmons, B., Yaksh, T. L., & Webb, M. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04451.x · Cited by 247
“Minocycline has been used to study the role of microglia in experimental models of brain ischemia (Yrjanheikki et al., 1999), traumatic brain injury (Sanchez Mejia et al., 2001), Huntington’s disease (Chen et al., 2000), Parkinson’s disease (Wu et al., 2002) and nerve injury-induced hyperalgesia…”
BackgroundSriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242
Carrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110
Xia, Y., Xiao, Y., Wang, Z.-H., Liu, X., Alam, A. M., Haran, J. P., McCormick, B. A., Shu, X., Wang, X., & Ye, K. (2023) · Nature Communications · doi:10.1038/s41467-023-41283-w · Cited by 108
Park, K. W., Baik, H. H., & Jin, B. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803392 · Cited by 84
Zhang, Q.-G., Wang, R.-M., Scott, E., Han, D., Dong, Y., Tu, J.-Y., Yang, F., Reddy Sareddy, G., Vadlamudi, R. K., & Brann, D. W. (2013) · Brain · doi:10.1093/brain/awt046 · Cited by 50
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Ashraf, T., Jiang, W., Hoque, M. T., Henderson, J., Wu, C., & Bendayan, R. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-91 · Cited by 40
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Metadata
- Authors
- Ryu, J. K., Franciosi, S., Sattayaprasert, P., Kim, S. U., & McLarnon, J. G.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2004-05-17
- Volume
- 48
- Issue
- 1
- Pages
- 85-90
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W1993862136
- Cited by
- 129
- References
- 7
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.